Prior Authorization Delays: A Growing Threat to Timely Cancer Care

For patients facing a cancer diagnosis, every moment counts. Yet, a growing administrative hurdle – prior authorization from insurance companies – is delaying access to necessary treatment, potentially impacting outcomes and increasing stress for patients and their families.

The Paperwork Problem

Prior authorization requires healthcare providers to obtain approval from insurers before certain medications, imaging scans, or procedures can be administered. While initially intended to prevent misuse and protect policyholders, the system has expanded significantly, now affecting routine care already supported by established clinical guidelines. The delays caused by this process can be particularly detrimental for those beginning cancer treatment, where time is of the essence.

Impact on Patient Care

A 2024 survey by the American Medical Association (AMA) revealed that 94% of physicians report prior authorization leading to delays in necessary care. Nearly one in three physicians report these delays lasting several weeks or even longer. For patients battling cancer, heart disease, or other serious chronic illnesses, these delays can lead to complications, additional procedures, and increased costs.

SB319: A Step Towards Transparency and Timeliness in Utah

In Utah, State Senator Wayne Harper is sponsoring SB319 to address these concerns. The bill aims to establish enforceable standards for prior authorization without eliminating the process entirely. Key provisions of SB319 include:

• Plain Language Requirements: Insurers must post their authorization requirements in clear, understandable language.
• Transparency in AI Use: If artificial intelligence is used to review authorization requests, insurers must disclose this fact.
• Timely Decisions: The bill sets firm timelines for approval decisions – five business days for standard requests and 72 hours for urgent care.
• Medical Judgment: Clinical denials must be based on independent medical judgment, not automated screening or unchecked recommendations.
• Continuity of Care: SB319 seeks to reduce repetitive reauthorization cycles for patients with stable chronic conditions.
• Public Reporting: Insurers will be required to publicly report approval rates, denial rates, appeal outcomes, and processing times to the Utah Insurance Department.

A Physician’s Perspective

Dr. Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, has firsthand experience with the challenges of prior authorization. Dr. Lewis, a pancreatic cancer survivor himself, understands the urgency of timely treatment. He also advocates for patient empowerment, encouraging individuals to ask questions and be honest with their physicians about symptoms and side effects. He emphasizes the importance of not allowing statistics to dictate a patient’s outlook.

Advancements in Pancreatic Cancer Treatment

Dr. Lewis is also involved in research exploring recent treatment options for pancreatic adenocarcinoma, including RAS(ON) inhibitors like RMC-6236, which have shown promising responses even in heavily pretreated patients. His work highlights the ongoing efforts to improve outcomes for those diagnosed with this challenging cancer.

The Path Forward

Reforms like SB319 represent a crucial step towards ensuring that oversight protects patients rather than creating unnecessary barriers to care. Timely access to treatment should not depend on navigating opaque processes or persistent fighting. Transparency, accountability, and a focus on medical judgment are essential to delivering the best possible care for all patients.